Prognostic markers for overall survival and outcome to LuPSMA radionuclide treatment in patients with metastatic castration-resistant prostate cancer.

Andrei Gafita,Jeremie Calais,Hui Wang,Manuel Weber,Hendrik Rathke,Clemens Kratochwil,Rouzbeh Esfandiari,Wesley R Armstrong,Shahneen Sandhu,Robert Tauber,Ebrahim Delpassand,Uwe Haberkorn,Wolfgang A. Weber,Ken Herrmann,Johannes Czernin,Michael S. Hofman,Wolfgang P. Fendler,Matthias Eiber

Prognostic markers for overall survival and outcome to LuPSMA radionuclide treatment in patients with metastatic castration-resistant prostate cancer.

2020

Andrei Gafita
Jeremie Calais
Hui Wang
Manuel Weber
Hendrik Rathke
Clemens Kratochwil
Rouzbeh Esfandiari
Wesley R Armstrong
Shahneen Sandhu
Robert Tauber
Ebrahim Delpassand
Uwe Haberkorn
Wolfgang A. Weber
Ken Herrmann
Johannes Czernin
Michael S. Hofman
Wolfgang P. Fendler
Matthias Eiber

5548Background: The aim of this international multicenter retrospective analysis was to identify prognostic markers for the clinical outcome in late-stage mCRPC patients treated with 177Lutetium-pr...

Keywords:

Oncology
in patient
overall survival
Prostate cancer
Pathology
castration resistant
Medicine
Internal medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations